C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
PNTV Equity

PNTV

OTCMKTS · PNTV

$0.01
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Underweight Conviction 2/5
27/100 composite
Fundamentals2
Regulatory49
Market40
Editorial30
Composite · trailing 12 months

Players Network carries an Underweight rating, with a 27.4 composite placing the shares firmly in the lowest rating band and conviction at 2/5. Regulatory is the strongest pillar at 49, driven by an 80 enforcement subscore, a 50 jurisdiction posture, and a weaker 25 cadence contribution. Market contributes 40 despite no quote being available from institutional pricing feeds, limiting price-based confirmation. Editorial contributes 30, reflecting no newsroom or brief activity in CIN newsroom coverage. Fundamentals contribute only 2, overwhelmingly defining the negative rating through failed growth, profitability, and capitalization measures.

Licensed fundamentals data show year-over-year revenue contracting by 78.2%, eliminating any operating-growth support for the equity case. Gross margin stands near negative 177%, while operating margin approaches negative 1,475%, indicating severe cost absorption and a business model operating far below economic scale. EBITDA is negative by roughly $3.8 million, and the cash-burn ratio is about 0.80, consistent with the stated stretched financial condition. The approximately $4.7 million market capitalization receives no tier credit, while cash runway supplies the fundamentals pillar’s only meaningful subscore at 15. Primary regulatory filings provide no latest filing date, and the record contains no regulatory events during either the trailing 90-day or 180-day periods. No enforcement hits support the regulatory pillar, but filing cadence remains deficient.

The clearest forward catalyst sits within regulatory, the highest-scoring pillar. A return to consistent primary regulatory filings would raise transparency around operations, capital structure, and financial continuity while directly addressing the weak cadence subscore. The favorable enforcement contribution and baseline jurisdiction posture already provide the strongest available support, but neither offsets collapsing revenue, deeply negative margins, negative EBITDA, absent institutional pricing, and limited CIN newsroom coverage. Regulatory progress therefore represents the most direct route to improved conviction, whereas continued silence reinforces the Underweight assessment and the stretched financial profile. The single most important signal to watch will be the appearance of a current primary regulatory filing that re-establishes a dependable reporting cadence.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
CEO
Mark Bradley
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$4.7M
Price to sales
15.81
Revenue (TTM)
$267K
Gross profit (TTM)
$-473K
EBITDA
$-3.8M
Operating margin
-1474.7%
Profit margin
0.0%
Rev growth YoY
-78.2%
Return on equity
0.0%
Return on assets
-149.1%
EPS (TTM)
$-0.02
Shares outstanding
678.1M
Insider ownership
3.6%
Institutional ownership
0.4%
Beta
-0.46
Full-time employees
2
GICS sector
Healthcare
GICS industry
Drug Manufacturers - Specialty & Generic
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for PNTV (PNTV)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for PNTV (PNTV), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (2 bullish signals, 0 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for PNTV are maintained by Cannabis Investor News and refreshed throughout the trading day.